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Abstract: We investigated the influences of liver histology， serum levels of hepatitis 
C virus (HCV) and HCV genotypes on responsiveness to interferon (IFN) therapy in 342 
patients with chronic hepatitis C. Either 9 million units (MU) of lymphoblastoid alpha IFN 
or 3 MU  of recombinant IFN -alpha was administered daily for 2 weeks and then three 
times a week for 22 weeks. IFN responses were divided into three groups on the basis of 
the results of polyri1erase chain reaction (PCR) assay detecting HCV-RNA in serum. 
Complete response (CR) was defined as sustained elimination of HCV for at least 6months 
after treatment， partial response (PR) as HCV elimination for a limited period， non 
response (NR) as continuously positive for HCV-RNA in serum. Quantitation of pre-
treament HCV-RNA amount in serum was determined by competitive PCR assay in 47 
patients. HCV genotyping was performed in 114 patients by PCR with genotype-specific 
primers. CR was obtained in 97 patients (28.4 %)， PR in 104 (30.4 %) and NR in 141 (41.2 
%). IFN responses， represented by CR/PR/NR， were 15/18/11 in 44 patients with chronic 
persistent hepatitis (CPH)， 72/65/73 in 210 patients with chronic aggressive hepatitis 
(CAH) 2 a， and 10/21/57 in 88 patients with CAH 2 b. CR rate was lower in patients with 
CAH 2 b (11.4 %) compared to those with CPH (34.1 %) or CAH 2 a (34.3 %). Averages 
of pre-treatment serum HeV-RNA amount (copies/50μ1) were 103.55 in 13 CRs， 104・56in 17 
PRs， and 105・95in 17 NRs. There was a positive correlation between pre-treatment HCV-
RNA levels and IFN unresponsiveness. HCV genotyping in 114 patients revealed that HCV 
type 1 infection was observed in one， type 1 in 94， type II in 11， type IV in 6 and mixed 
(types Ii and IV) in 2 patients， and their IFN responses (CR/PR/NR) were 0/0/1， 28/26/ 
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40， 3/5/3， 1/3/2 and 0/1/1， respectively. 
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Hepatitis C virus CHCV) is the causative agent of chronic hepatitis C， which progresses to 
liver cirrhosis and hepatocellular carcinoma CHCC)l-3). Recently， interferon (IFN) administra-
tion has been reported effective for chronic hepatitis C4-6)， and the efficacy of IFN therapy for 
chronic hepatitis C is being established worldwide. 
Since J anuary 1992， we have treated 493 patients with chronic hepatitis C by IFN -alpha. In 
this report， we evaluated the efficacy of IFN therapy and analyzed the factors determining the 
IFN responsiveness in our own experience of treating patients with chronic hepatitis C by IFN 
-alpha. 
P ATIENTS AND METHODS 
Patients 
A total of 493 consecutive J apanese patients with histologically proven chronic hepatitis 
received IFN-alpha therapy CTable 1). All patients had anti-HCV Canti-C 100.3 or anti-HCV 
core) detected by the Ortho Diagnostics RIA and al were negative for serological markersof 
HBV infection Cabsence of HBsAg and anti-HBc). All patients gave their written informed 
consent for participation. 
Interferon 
Either natural IFN-alpha CnIFN， human lyphoblastoid IFN， Sumitomo Pharmaceuticals Co.， 
Osaka) or recombinant IF:N-alpha 2 a CrIFN， Takeda Chem. Ind. Co. Ltd.， Osaka) was used at 
daily doses of 3 million units CMU) or 9 MU， respectively. nIFN or rIFN was given 7 times 
a week for the initial 2 weeks and subsequently 3 times. a week for 22 weeks. 
Examinations and follow-up 
Liver biopsy was performed before IFN therapy in al patients and liver histology was 
assessed according to the European classification7). Biochemical examination of blood was 
Table 1. Charact巴risticsof pa tients 
Variable Values 
Patients 493 
Men and woman 34， 149 
Average age at start of therapy 49目4





natural IFN ct 302 
recombinant IFNα 191 
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done at 2-to 4-week intervals. 
Definition of response to IFN -alpha 
Reverse transcription and the polymerase chain reaction (RT-PCR) method detecting HCV 
-RNA encoding the NS 5 region8) was used to evaluate IFN reponses. Complete response (CR) 
was defined as sustained disappearance of HCV-RNA in sera for more than 6 months after the 
end of IFN treatment. Partial response (PR) was defined as tempory elimination of HCV in 
IFN treatment period and non-response (NR) as continuing positivity of HCV-RNA through目
out the treatment and follow-up periods. 
Genotyping of HCV and quantification of HCV -RN A in自erum
The genotyping of HCV was performed by the PCR method using type-specific primers that 
recognize the core region of HCV as reported9). HCV-RNA in serum before IFN therapy was 
quantified by a competitive PCR assay using synthetic mutant RNA with a novel restriction 
endonuc1ease (Kpn 1) site10)， which was generated by site-directed mutagenesis and in vitro 
transcription 
Statistics 
We used Student's t test for the evaluation of statistical differences. 
IFN response 
IFN response was evaluated in 342 patients who had been followed more than 6 months after 
the end of IFN therapy. As shown in Table 2， 97 patients (28.4 %) were c1assified as CR， 104 
(30.4 %) as PR， and 141 (41.2 %) as NR. A statistical difference in CR rate was not observed 
either between males and females or between nIFN -treated and rIFN -treated patients. Table 
3 shows the relation between IFN responses and alanine aminotransferase (AL T) levels. 
Sustained normalization of AL T levels was obtained in 91 patients in tota1. Eighty-seven (89.7 
%) out of 97 complete responders showed normal AL T levels. Four patients with sustained 
normal ALTlevels were positive for serum HCV-RNA at the last examinations (2 patients 
Table 2目 IFNresponses 
Total Male Female nIFNα rIFN a 
n=342 n=232 n=110 n=187 nニ 15
CR 97 (28.4%) 60 (25.9%) 37 (33.6%) 47 (25.1%) 50 (32目3%)
PR 104 (30.4%) 67 (28.9%) 37 (33.6%) 45 (24.1%) 59 (38.1%) 
NR 141 (4l. 2%) 105 (45.3%) 36 (32.7%) 95 (50.8%) 46 (29.6%) 
Table 3. Relashion between HCV-RNA detection and ALT level 
Total Sustained nomalization of AL T level 
n=342 yes: n=91 no :n=251 
CR 97 87 10 
PR 104 2 102 
NR 141 2 139 
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showed PR and 2 showed NR). 
Rekationship between liver histology and IFN response (Table 4) 
There was no difference inCR rate between patients with CPH (34.1 %) and those with 
CAH 2 a (34.3 %). However， a lower CR rate was observed in patients with CAH 2 b (11.4 
%). The NR rates of patients with CPH， CAH 2 a or CAH 2 b were 25.0 %， 34.3 % and 64.8 
%， respectively. 
Relationship between pre-treatment serum HCV-RNA amount and IFN response 
Serum HCV-RNA amount before IFN treatment was examined in 47 patients 03 complete 
responders， 17 partial responders and 17 non-responders， Fig. 1). The average serum HCV-
RNA amount was 103.55 copies/50μin complete responders， 104・65 copies/50μin partial 
responders and 105.97 copies/50μ1 in non-responders. There were no complete responders who 
showed over 105 copies/50μ1 of HCV-RNA amount before IFN treatment. Serum HCV-RNA 
amounts in NR and PR patients were significantly higher than those in CR patients. 
Relationship between pre-treatment HCV-RNA amount in serum and liver histology 
The averages of serum HCV-RNA amount were 104.04 (copies/50μ1) in 14 patients with 
CPH， 104.64 in 26 with CAH 2 a， .and 105・17in 9 with CAH 2 b (Fig. 2). Therer was a tendency 
for serum HCV -RN A amount to be related to histological severity of liver disorders 
HCV genotype and IFN responsiveness 
HCV genotyping was performed in 114 patients， who composed of 32 complete responders， 35 
partial responders and 47 non-responders. As shown in Table 5， 94 patients infected with type 
I of HCV (HCV -II) resulted in 28 CRs， 26 PRs， and 40 NRs. Eleven infected with type II of 
HCV (HCV-III) resulted in 3 CRs， 5 PRs and 3 NRs. Six patients with type IV of HCV (HCV 
IV) in one CR， 3 PRs and 2 NRs. The case infected with type 1 of HCV (HCV -1 ) was a non 
responder hemophiliac. Both of the two patients infected with HCV -I and IV had experiences 
Table 4. Relationship between liver histologi巴sand IFN r巴spons巴S
CPH CAH2a CAH2b 


















Table 5. Relationship between HCV genotypes and IFN responses 
Type 1 Type I Type II Type IV Type II+IV 
(n=l) (n=94) (n=11) (nニ 6) (n=2) 
CR 28 l 
PR 26 5 3 
NR 40 3 2 
























































































Fig. 3. Relationship b巴tweenpre 
tr巴atment serum HCV 
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of massive transfusion and their IFN responses were PR and NR. 
DISCUSSION 
IFN -alpha is recognized as an useful drug for treatment of chronic hepatitis C. Its efficacy 
has been mostly evaluated by means of serum AL T levels and improvement of liver histological 
findings5，6). In addition， recent advances of diagnostic techniques， inc1uding the application of 
the PCR for detection of HCV-RNA， al10wed us to evaluate IFN responses on the basis of the 
presence or absence of HCV in serum. In the present study， we evaluated IFN responses 
virological1y using PCR technique and investigated several background factors that might 
affect IFN responses， such as liver histology， pre-treatment HCV-RNA amount in semum and 
H CV genotype. 
Our first question was whether IFN responses determined by serum HCV-RNA using a RT 
PCR method differed from those determined by AL T values. In treating 342 patients with 
chronic hepatitis C， HCV elimination was obtained in 97 patients and sustained normalization 
of ALT in 91 patients. Eighty-seven patients showed both HCV elimination and sustained 
normalization of AL T levels， which corresponded to 89.7 % and 95.6 % of patients who 
obtained sustained HCV elimination or ALT normalization， respectively. The evaluations of 
IFN response by ALT value were almost the same as those determined by HCV-RNA 
elimination. We therefore conc1ude that AL T value is c1inical1y sufficient for evaluation of 
IFN therapy. 
(474) M. Y oshikawa， etal. 
We next investigated liver histo1ogy， which is thought to be one of the factors determining 
IFN responses11 •12). Patients with CAH 2 a responded to IFN beUer than those with CAH 2 b 
in the present study. Simi1ar observations were a1so reported by others13•14). The histo1ogica1 
severity seemed to correlate to poor responsiveness to IFN therapy. However， we cou1d not 
find a beUer responsiveness in patients with CPH than in those with CAH 2 a 
As another factor inf1uencing IFN responsiveness， HCV titer in serum shou1d be considered. 
We determined pre-treatment HCV-RNA amount by competitive PCR assay. Comp1ete 
responders had 10wer pre-treatment HCV -RN A 1eve1s than those in partia1 responders and non 
responders. These resu1ts suggest that pre-treatment HCV-RNA amount in serum is another 
important predictor of IFN responses. To exclude the inf1uence of HCV genotypes on IFN 
responses， we a1so examined the re1ation between pre-treatment HCV-RNA amount and IFN 
response in patients who were infected with an identica1 genotype of HCV， HCV -I (Fig. 3)， 
and a simi1ar resu1t was obtained. The pre-treatment HCV -RN A amount seemed to be re1ated 
to histo1ogica1 severity of liver disorder. However， itis noteworthy that there existed some 
patients with CPH who showed high 1eve1 of HCV vir百 nia. This may be the reason why we 
cou1d not obtain a beUer responsiveness in patients with CPH. In fact， two patients out of three 
with CPH and high 1eve1 of pre-treatment HCV-RNA， over 106 (copies/50μ1)， revea1ed NR to 
the therapy. Recent1y， Lau et aF5) a1so reported a simi1ar observation and insisted that the 1eve1 
of viremia was not necessarily corre1ated to 1iver histo1ogy. 
It was reported that IFN responsiveness might vary among different HCV genotypes16-18). 
Patients infected with genotype HCV -I are considered to be more resistant to IFN therapy 
than those with genotype HCV -II or HCV -IV. In the present study， the re1ationship of vira1 
genotypes to IFN response cou1d not be definite1y eva1uated， because most of our patients (96 
of 118 patients， 84.2 %) were classified to genotype HCV-II. Those with genotype HCV-III or 
HCV-IV were on1y 11 (9.7%) and 6 (5.3 %) patients， respective1y. A 1arger number of 
patients shou1d be examined for their infected HCV genotypes to determine whether HCV -II 
or HCV -IV is more sensitive to IFN therapy. It was， however， proven that about one third of 
patients infected with HCV -I were ab1e to 
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